helenalin has been researched along with Acute Myelogenous Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel Ghani, L; Dörner, W; Frank, D; Harki, DA; Khandanpour, C; Klempnauer, KH; Moorthy, R; Widen, JC; Yusenko, MV | 1 |
| Berdel, WE; Coulibaly, A; Jakobs, A; Klempnauer, KH; Müller-Tidow, C; Schlenke, P; Schmidt, TJ; Schomburg, C; Steinmann, S; Uttarkar, S | 1 |
2 other study(ies) available for helenalin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells.
Topics: 3T3 Cells; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Cell Line; Cell Line, Tumor; Gene Expression Regulation; HEK293 Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Ligands; Mice; Mice, Inbred C57BL; Promoter Regions, Genetic; Sesquiterpenes, Guaiane; THP-1 Cells; Transcriptional Activation | 2022 |
An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Protein Isoforms; Sesquiterpenes; Sesquiterpenes, Guaiane | 2016 |